CIDARA THERAPEUTICS INC (CDTX)

US1717572069 - Common Stock

26.62  -0.68 (-2.49%)

Fundamental Rating

2

Overall CDTX gets a fundamental rating of 2 out of 10. We evaluated CDTX against 564 industry peers in the Biotechnology industry. CDTX has a bad profitability rating. Also its financial health evaluation is rather negative. CDTX has a expensive valuation and it also scores bad on growth.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

CDTX had negative earnings in the past year.
CDTX had a negative operating cash flow in the past year.
CDTX had negative earnings in each of the past 5 years.
CDTX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

CDTX's Return On Assets of -75.85% is on the low side compared to the rest of the industry. CDTX is outperformed by 68.58% of its industry peers.
CDTX has a Return On Equity (-106.49%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -75.85%
ROE -106.49%
ROIC N/A
ROA(3y)-53.77%
ROA(5y)-68.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 236.76%, CDTX belongs to the best of the industry, outperforming 99.82% of the companies in the same industry.
CDTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 236.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

CDTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CDTX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CDTX has been increased compared to 5 years ago.
CDTX has a worse debt/assets ratio than last year.

2.2 Solvency

CDTX has an Altman-Z score of -1.01. This is a bad value and indicates that CDTX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.01, CDTX perfoms like the industry average, outperforming 57.81% of the companies in the same industry.
CDTX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
CDTX has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: CDTX outperforms 47.40% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.01
ROIC/WACCN/A
WACC10.61%

2.3 Liquidity

CDTX has a Current Ratio of 3.54. This indicates that CDTX is financially healthy and has no problem in meeting its short term obligations.
CDTX has a Current ratio of 3.54. This is comparable to the rest of the industry: CDTX outperforms 42.19% of its industry peers.
A Quick Ratio of 3.54 indicates that CDTX has no problem at all paying its short term obligations.
With a Quick ratio value of 3.54, CDTX perfoms like the industry average, outperforming 43.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.54
Quick Ratio 3.54

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 11.28% over the past year.
Looking at the last year, CDTX shows a very negative growth in Revenue. The Revenue has decreased by -53.63% in the last year.
The Revenue has been growing by 74.31% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)11.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.11%
Revenue 1Y (TTM)-53.63%
Revenue growth 3Y74.31%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, CDTX will show a decrease in Earnings Per Share. The EPS will decrease by -1.87% on average per year.
Based on estimates for the next years, CDTX will show a decrease in Revenue. The Revenue will decrease by -4.82% on average per year.
EPS Next Y-419.18%
EPS Next 2Y-48%
EPS Next 3Y-26.13%
EPS Next 5Y-1.87%
Revenue Next Year-89.17%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-4.82%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CDTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as CDTX's earnings are expected to decrease with -26.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48%
EPS Next 3Y-26.13%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CDTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CIDARA THERAPEUTICS INC

NASDAQ:CDTX (1/3/2025, 8:26:23 PM)

26.62

-0.68 (-2.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners52.11%
Inst Owner Change176.42%
Ins Owners1.24%
Ins Owner Change-0.02%
Market Cap291.22M
Analysts85
Price Target32.84 (23.37%)
Short Float %0.33%
Short Ratio0.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)50.61%
Min EPS beat(2)43.48%
Max EPS beat(2)57.74%
EPS beat(4)3
Avg EPS beat(4)-213.59%
Min EPS beat(4)-1017.65%
Max EPS beat(4)62.05%
EPS beat(8)5
Avg EPS beat(8)-80.66%
EPS beat(12)8
Avg EPS beat(12)-48.6%
EPS beat(16)9
Avg EPS beat(16)-26.57%
Revenue beat(2)0
Avg Revenue beat(2)-96.85%
Min Revenue beat(2)-100%
Max Revenue beat(2)-93.7%
Revenue beat(4)2
Avg Revenue beat(4)-28.16%
Min Revenue beat(4)-100%
Max Revenue beat(4)49.35%
Revenue beat(8)4
Avg Revenue beat(8)-7.77%
Revenue beat(12)7
Avg Revenue beat(12)2.2%
Revenue beat(16)9
Avg Revenue beat(16)6.09%
PT rev (1m)5.57%
PT rev (3m)8.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)36.16%
EPS NY rev (1m)0.85%
EPS NY rev (3m)5.99%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-94.83%
Revenue NY rev (1m)-33.33%
Revenue NY rev (3m)-37.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.05
P/FCF N/A
P/OCF N/A
P/B 2.52
P/tB 2.52
EV/EBITDA N/A
EPS(TTM)-6.92
EYN/A
EPS(NY)-10.51
Fwd EYN/A
FCF(TTM)-14.64
FCFYN/A
OCF(TTM)-14.61
OCFYN/A
SpS2.41
BVpS10.57
TBVpS10.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -75.85%
ROE -106.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 236.76%
FCFM N/A
ROA(3y)-53.77%
ROA(5y)-68.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 144.13%
Cap/Sales 1.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.54
Quick Ratio 3.54
Altman-Z -1.01
F-Score2
WACC10.61%
ROIC/WACCN/A
Cap/Depr(3y)177.39%
Cap/Depr(5y)121.58%
Cap/Sales(3y)0.35%
Cap/Sales(5y)0.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.11%
EPS Next Y-419.18%
EPS Next 2Y-48%
EPS Next 3Y-26.13%
EPS Next 5Y-1.87%
Revenue 1Y (TTM)-53.63%
Revenue growth 3Y74.31%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-89.17%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-4.82%
EBIT growth 1Y-26.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-612.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-614.28%
OCF growth 3YN/A
OCF growth 5YN/A